首页> 美国卫生研究院文献>ACS Medicinal Chemistry Letters >19F-NMR-Based Dual-Site ReporterAssay for the Discovery and Distinction of Catalytic and AllostericKinase Inhibitors
【2h】

19F-NMR-Based Dual-Site ReporterAssay for the Discovery and Distinction of Catalytic and AllostericKinase Inhibitors

机译:基于19F-NMR的双站记者催化和变构的发现和区别测定激酶抑制剂

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

In modern kinase drug discovery, allosteric inhibitors have become a focus of attention due to their potential selectivity, but such compounds are difficult to identify. Here we describe an NMR-based competition assay using 19F-containing reporter molecules, which allows for rapid identification and discrimination between ATP-competitive and allosteric kinase inhibitors. We illustrate the principle of such a dual-site competition assay with the example of catalytic and allosteric ABL1 kinase inhibitors. The assay can also be used to identify and characterize mixed binding modes of well-known drugs, as shown for crizotinib and fingolimod.
机译:在现代激酶药物发现中,变构抑制剂由于其潜在的选择性而已成为人们关注的焦点,但这类化合物难以鉴定。在这里,我们描述了使用含 19 F的报告分子的基于NMR的竞争测定,该测定可快速识别和区分ATP竞争性和变构激酶抑制剂。我们以催化和变构ABL1激酶抑制剂为例,说明了这种双位竞争试验的原理。该测定法还可用于鉴定和表征众所周知的药物的混合结合模式,如克唑替尼和芬戈莫德所示。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号